Skip to main content

Table 3 The summary of sensitivity analyses

From: Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis

Sensitivity analysis Subjects
SGLT-2 inhibitors GLP-1 RAs Comparison Risk ratio 95% CI I2 (%) p value
MACE-3
 MACE-3 as the primary outcome 17514 10644 SGLT-2 inhibitors vs. placebo 0.87 0.76–1.00 50.4 0.033
   GLP-1 RAs vs. placebo 0.91 0.79–1.04   
   SGLT-2 inhibitors vs. GLP-1 RAs 0.96 0.79–1.17   
 Without ELIXA 20106 14007 SGLT-2 inhibitors vs. placebo 0.85 0.75–0.97 49.5 0.037
   GLP-1 RAs vs. placebo 0.88 0.76–1.03   
   SGLT-2 inhibitors vs. GLP-1 RAs 0.97 0.79–1.18   
 Daily GLP-1 RAs 20106 6635 SGLT-2 inhibitors vs. placebo 0.84 0.75–0.96 47.7 0.053
   GLP-1 RAs vs. placebo 0.86 0.73–1.02   
   SGLT-2 inhibitors vs. GLP-1 RAs 0.99 0.80–1.21   
 Weekly GLP-1 RAs 20106 4009 SGLT-2 inhibitors vs. placebo 0.85 0.76–0.95 31.8 0.19
   GLP-1 RAs vs. placebo 1.01 0.83–1.22   
   SGLT-2 inhibitors vs. GLP-1 RAs 0.85 0.68–1.05   
 GLP-1 analogues 20106 6068 SGLT-2 inhibitors vs. placebo 0.85 0.76–0.95 30.6 0.17
   GLP-1 RAs vs. placebo 0.81 0.69–0.95   
   SGLT-2 inhibitors vs. GLP-1 RAs 1.05 0.86–1.27   
 Exendin-4 analogues 20106 4576 SGLT-2 inhibitors vs. placebo 0.85 0.77–0.94 28.7 0.21
   GLP-1 RAs vs. placebo 1.03 0.88–1.20   
   SGLT-2 inhibitors vs. GLP-1 RAs 0.83 0.69–0.99   
Renal outcomes
 Renal endpoints as secondary outcomes 18583 7534 SGLT-2 inhibitors vs. placebo 0.67 0.55–0.83 0 0.86
   GLP-1 RAs vs. placebo 0.86 0.72–1.03   
   SGLT-2 inhibitors vs. GLP-1 RAs 0.78 0.59–1.03   
 Macroalbuminuria 1505 7534 SGLT-2 inhibitors vs. placebo N/A N/A 0 0.73
   GLP-1 RAs vs. placebo 0.91 0.81–1.02   
   SGLT-2 inhibitors vs. GLP-1 RAs N/A N/A   
 Weekly GLP-1 RAs 20088 5376 SGLT-2 inhibitors vs. placebo 0.65 0.55–0.78 0 0.73
   GLP-1 RAs vs. placebo 0.91 0.81–1.02   
   SGLT-2 inhibitors vs. GLP-1 RAs 0.71 0.58–0.89   
 GLP-1 analogues 20088 4357 SGLT-2 inhibitors vs. placebo 0.68 0.59–0.78 0 0.94
   GLP-1 RAs vs. placebo 0.82 0.66–1.01   
   SGLT-2 inhibitors vs. GLP-1 RAs 0.83 0.65–1.07   
  1. SGLT2i sodium-glucose cotransporter-2 inhibitors, GLP-1 RAs glucagon-like peptide-1 receptor agonists, CI confidence intervals, MACE-3 3-point major adverse cardiovascular event, vs. versus, N/A not available